Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CRBP moved a median of +0.42% 30 minutes after news, and +0.12% by the close. How CRBP actually reacts to news — the realized, point-in-time move the market made, measured across 305 labeled events over the last three years with zero look-ahead.
CRBP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 302 |
| 30-min | +0.42% | 53% | 305 |
| 60-min | +0.14% | 55% | 305 |
| to close | +0.12% | 51% | 299 |
| Middle 50% of CRBP reactions | -1.85% to +2.77% |
|---|---|
| Median reaction (30-min) | +0.42% |
| Measured reactions | 305 |
Half of all Corbus Pharmaceuticals Holdings, Inc. news events land between -1.85% and +2.77% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRBP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -0.41% | 46% | -0.91% |
| Coverage initiations | 36 | -2.71% | 25% | -3.72% |
| Rating reiterations | 66 | -0.23% | 38% | -1.11% |
| Price-target cuts | 13 | -0.08% | 39% | -0.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CRBP ranks against every other measured name →
That’s how CRBP usually reacts — get an email when it moves on news →Email me when CRBP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRBP's baseline. Nothing else.
Recent CRBP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Corbus Pharmaceuticals For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +1.41% | |
| Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer | Press release | GlobeNewswire | +1.30% | -4.33% | |
| Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity | Press release | GlobeNewswire | -0.76% | +1.89% | |
| Form 8-K Corbus Pharmaceuticals For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | +1.89% | |
| Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity | Press release | GlobeNewswire | -0.76% | +1.89% | |
| Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.24% | +1.70% | |
| Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +0.49% | +5.41% | |
| Form 10-Q Corbus Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.23% | +4.42% | |
| Form 8-K Corbus Pharmaceuticals For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +5.41% | |
| Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity | Press release | GlobeNewswire | +1.24% | +3.98% | |
| Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer | Press release | GlobeNewswire | -0.98% | -0.60% | |
| Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer | Press release | GlobeNewswire | -1.02% | -3.74% | |
| Form 8-K Corbus Pharmaceuticals For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -1.02% | -3.74% | |
| Form S-8 Corbus Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +0.97% | +0.00% | |
| Form S-8 Corbus Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | -2.04% | -1.40% | |
| Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers | Press release | GlobeNewswire | -7.18% | -18.87% | |
| Form 8-K Corbus Pharmaceuticals For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -7.18% | -18.87% | |
| Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call | Press release | GlobeNewswire | +0.30% | +16.26% | |
| Form 8-K Corbus Pharmaceuticals For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +16.26% | |
| Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors | Press release | GlobeNewswire | -0.49% | -1.96% | |
| Form 8-K Corbus Pharmaceuticals For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | -1.96% | |
| Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.55% | +6.11% | |
| Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +2.04% | +1.60% | |
| Form 10-Q Corbus Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.55% | +6.11% | |
| Form 8-K Corbus Pharmaceuticals For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +2.04% | +1.60% | |
| Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 | Press release | GlobeNewswire | -0.42% | +0.38% | |
| Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 | Press release | GlobeNewswire | -2.15% | +0.29% | |
| Form 8-K Corbus Pharmaceuticals For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | +3.32% | |
| Form DEFA14A Corbus Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -0.29% | +3.32% | |
| Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity | Press release | GlobeNewswire | +0.89% | -1.28% | |
| Form 8-K Corbus Pharmaceuticals For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -1.28% | |
| Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer | Press release | GlobeNewswire | -0.75% | -2.36% | |
| Form 8-K Corbus Pharmaceuticals For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.80% | |
| Form ARS Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.87% | -2.12% | |
| Form DEF 14A Corbus Pharmaceuticals For: Apr 01 | SEC filing · Form DEF | SEC EDGAR | +0.87% | -2.12% | |
| Form DEFA14A Corbus Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.87% | -2.12% | |
| Form EFFECT Corbus Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +3.90% | -3.33% | |
| Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit | Press release | GlobeNewswire | -0.70% | -5.04% | |
| Form S-3 Corbus Pharmaceuticals | SEC filing · Form S-3 | SEC EDGAR | -1.95% | -4.48% | |
| Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +5.01% | +16.75% | |
| Form 10-K Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.52% | +3.40% | |
| Form 8-K Corbus Pharmaceuticals For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +5.01% | +16.75% | |
| Form 8-K Corbus Pharmaceuticals For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +1.70% | |
| Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference | Press release | GlobeNewswire | +1.70% | +2.49% | |
| Form 8-K Corbus Pharmaceuticals For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.58% | -2.68% | |
| Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.26% | -1.14% | |
| Form 8-K Corbus Pharmaceuticals For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -0.37% | |
| Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | Press release | GlobeNewswire | +5.13% | -6.29% | |
| Form 8-K Corbus Pharmaceuticals For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +5.13% | -6.29% | |
| Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 | Press release | GlobeNewswire | +5.13% | -6.29% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRBP section they belong to.
Where else CRBP is measured.
CRBP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 306 | +0.04% | 51% |
| U.S. Physical Therapy, Inc. (USPH) | 304 | -0.03% | 46% |
| The Cooper Companies, Inc. (COO) | 303 | -0.21% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Corbus Pharmaceuticals Holdings, Inc.'s median reaction calculated?
Every labeled CRBP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 305 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CRBP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRBP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.